Natera develops and commercialises cell-free DNA (cfDNA) genetic tests across three clinical areas: oncology, women's health, and organ health. Its core proposition is the detection of disease at earlier stages through the analysis of DNA fragments circulating in the bloodstream, with the company claiming sensitivity down to a single molecule in a tube of blood. The underlying platform combines proprietary molecular biology techniques with bioinformatics software and artificial intelligence.
The company's principal products are Panorama™, a prenatal screening test; Signatera™, a personalised cancer detection test; and Prospera™, a transplant monitoring test - each described as market-leading in its category. Clinical laboratory operations are run from two sites: Austin, Texas, and San Carlos, California, both holding CLIA certification. The laboratories are also CAP-accredited and ISO 13485-certified. Natera serves patients and healthcare providers worldwide.
The company's scientific output includes more than 300 peer-reviewed publications, reflecting a research-intensive approach to developing and validating its diagnostics. Its stated mission is to make personalised genetic testing part of the standard of care, with an emphasis on earlier and more targeted clinical interventions.
Technical work at Natera spans molecular biology, bioinformatics, AI, clinical laboratory operations, and regulatory compliance - reflecting the breadth of disciplines required to move from assay development through to accredited clinical delivery at global scale.